Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria
Sign Up to like & getrecommendations! Published in 2021 at "Hepatology Research"
DOI: 10.1111/hepr.13693
Abstract: A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (HCC). In this study, we evaluated this therapeutic combination in a real‐world setting, with a focus… read more here.
Keywords: hepatocellular carcinoma; unresectable hepatocellular; atezolizumab plus; patients meet ... See more keywords